Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Bladder Cancer

  Free Subscription

Articles published in Cancer Res

Retrieve available abstracts of 23 articles:
HTML format

Single Articles

    September 2021
  1. YANG L, Sun J, Li M, Long Y, et al
    Oxidized low-density lipoprotein links hypercholesterolemia and bladder cancer aggressiveness by promoting cancer stemness.
    Cancer Res. 2021 Sep 3. pii: 0008-5472.CAN-21-0646.
    PubMed     Abstract available

  2. PARK S, Rong L, Owczarek TB, Di Bernardo M, et al
    Novel mouse models of bladder cancer identify a prognostic signature associated with risk of disease progression.
    Cancer Res. 2021 Sep 1. pii: 0008-5472.CAN-21-1254.
    PubMed     Abstract available

    April 2021
  3. FUHRMAN BJ, Moore SC, Byrne C, Makhoul I, et al
    Association of the Age at Menarche with Site-Specific Cancer Risks in Pooled Data from Nine Cohorts.
    Cancer Res. 2021;81:2246-2255.
    PubMed     Abstract available

    March 2021
  4. WULLWEBER A, Strick R, Lange F, Sikic D, et al
    Bladder Tumor Subtype Commitment Occurs in Carcinoma In Situ Driven by Key Signaling Pathways Including ECM Remodeling.
    Cancer Res. 2021;81:1552-1566.
    PubMed     Abstract available

  5. SOTTNIK JL, Vanderlinden LA, Joshi M, Chauca-Diaz A, et al
    Androgen Receptor Regulates CD44 Expression in Bladder Cancer.
    Cancer Res. 2021 Mar 9. pii: 0008-5472.CAN-20-3095.
    PubMed     Abstract available

    November 2020
  6. DOMINGUEZ GUTIERREZ PR, Kwenda EP, Donelan W, O'Malley P, et al
    Hyal2 expression in tumor-associated myeloid cells mediates cancer-related inflammation in bladder cancer.
    Cancer Res. 2020 Nov 25. pii: 0008-5472.CAN-20-1144.
    PubMed     Abstract available

    August 2020
  7. BELLMUNT J, Kim J, Reardon B, Perera-Bel J, et al
    Genomic predictors of good outcome, recurrence or progression in High grade T1 non-muscle invasive bladder cancer.
    Cancer Res. 2020 Aug 31. pii: 0008-5472.CAN-20-0977.
    PubMed     Abstract available

    July 2020
  8. KIKUCHI H, Maishi N, Annan DA, Alam MT, et al
    Chemotherapy-Induced IL8 Upregulates MDR1/ABCB1 in Tumor Blood Vessels and Results in Unfavorable Outcome.
    Cancer Res. 2020;80:2996-3008.
    PubMed     Abstract available

  9. BUI NHB, Napoli M, Davis AJ, Abbas HA, et al
    Spatiotemporal Regulation of DeltaNp63 by TGFbeta-Regulated miRNAs Is Essential for Cancer Metastasis.
    Cancer Res. 2020;80:2833-2847.
    PubMed     Abstract available

    February 2020
  10. HU B, Wang Z, Zeng H, Qi Y, et al
    Blockade of DC-SIGN+ tumor-associated macrophages reactivates anti-tumor immunity and improves immunotherapy in muscle-invasive bladder cancer.
    Cancer Res. 2020 Feb 14. pii: 0008-5472.CAN-19-2254.
    PubMed     Abstract available

    January 2020
  11. LOH XY, Sun QY, Ding LW, Mayakonda A, et al
    RNA-Binding Protein ZFP36L1 Suppresses Hypoxia and Cell-Cycle Signaling.
    Cancer Res. 2020;80:219-233.
    PubMed     Abstract available

    February 2019
  12. WANG Z, Cao D, Qi Z, Pang Y, et al
    Retinoic acid-related orphan receptor C regulates proliferation, glycolysis, and chemoresistance via the PD-L1/ITGB6/STAT3 signaling axis in bladder cancer.
    Cancer Res. 2019 Feb 26. pii: 0008-5472.CAN-18-3842.
    PubMed     Abstract available

    September 2018

  13. Editor's Note: Curcumin Potentiates the Antitumor Effects of Bacillus Calmette-Guerin against Bladder Cancer through the Downregulation of NF-kappaB and Upregulation of TRAIL Receptors.
    Cancer Res. 2018;78:5182.

    May 2018
  14. CHEN A, Fu G, Xu Z, Sun Y, et al
    Detection of Bladder Cancer Via Microfluidic Immunoassay and Single-Cell DNA Copy Number Alteration Analysis of Captured Urinary Exfoliated Tumor Cells.
    Cancer Res. 2018 May 22. pii: 0008-5472.CAN-17-2615.
    PubMed     Abstract available

    March 2018
  15. YU C, Liu Z, Chen Q, Li Y, et al
    Nkx2.8 Inhibits Epithelial-Mesenchymal Transition in Bladder Urothelial Carcinoma via Transcriptional Repression of Twist1.
    Cancer Res. 2018;78:1241-1252.
    PubMed     Abstract available

    February 2018
  16. DAIZUMOTO K, Yoshimaru T, Matsushita Y, Fukawa T, et al
    A DDX31/mutant-p53/EGFR axis promotes multistep progression of muscle invasive bladder cancer.
    Cancer Res. 2018 Feb 13. pii: 0008-5472.CAN-17-2528.
    PubMed     Abstract available

    January 2018
  17. OOKI A, Del Carmen Rodriguez Pena M, Marchionni L, Dinalankara W, et al
    YAP1 and COX2 Coordinately Regulate Urothelial Cancer Stem-like Cells.
    Cancer Res. 2018;78:168-181.
    PubMed     Abstract available

    September 2017
  18. GOLDSTEIN JT, Berger AC, Shih J, Duke FF, et al
    Genomic activation of PPARG reveals a candidate therapeutic axis in bladder cancer.
    Cancer Res. 2017 Sep 18. pii: canres.1701.2017.
    PubMed     Abstract available

  19. DUEX JE, Owens C, Chauca-Diaz A, Dancik GM, et al
    Nuclear CD24 Drives Tumor Growth and Is Predictive of Poor Patient Prognosis.
    Cancer Res. 2017;77:4858-4867.
    PubMed     Abstract available

    April 2017
  20. VAN KAMPEN JGM, van Hooij O, Jansen CF, Smit FP, et al
    miRNA-520f Reverses Epithelial-to-Mesenchymal Transition by Targeting ADAM9 and TGFBR2.
    Cancer Res. 2017;77:2008-2017.
    PubMed     Abstract available

    March 2017
  21. NICHOLSON J, Jevons S, Groselj B, Ellermann S, et al
    E3 ligase cIAP2 mediates downregulation of MRE11 and radiosensitization in response to HDAC inhibition in bladder cancer.
    Cancer Res. 2017 Mar 31. pii: canres.3232.2016.
    PubMed     Abstract available

    February 2017
  22. MIAO L, Liu Q, Lin CM, Luo C, et al
    Targeting Tumor-Associated Fibroblasts for Therapeutic Delivery in Desmoplastic Tumors.
    Cancer Res. 2017;77:719-731.
    PubMed     Abstract available

    January 2017
  23. OWCZAREK TB, Kobayashi T, Ramirez R, Rong L, et al
    ARF confers a context-dependent response to chemotherapy in muscle invasive bladder cancer.
    Cancer Res. 2017 Jan 12. pii: canres.2621.2016.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.